NEW YORK, NY— July 17, 2017 — Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and …
Capital Markets
WallachBeth Capital acts as Co-Book-Running Manager for AzurRx BioPharma in its Initial Public Offering
NEW YORK, NY— October 19, 2016—AzurRx BioPharma Inc. (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for …
WallachBeth Capital acts as Joint Book-Running Manager for VistaGen Therapeutics, Inc. in $10 Million Public Offering
NEW YORK, NY— May 13, 2016—VistaGen Therapeutics, Inc. (OTCQB: VSTA) (VistaGen or the Company), a clinical-stage biopharmaceutical company dedicated to …